WI Watchlist: FluGen, Propeller Health, Gener8tor, EnSync | Jeff Bauter Engel | 02/15/19 | Wisconsin |
NIH Using Vaccines from Madison Startup FluGen in New Clinical Trial | Jeff Buchanan | 09/19/18 | Wisconsin |
With BioNTech Deal, Pfizer Becomes Latest to Bet on mRNA Vaccines | Ben Fidler | 08/16/18 | New York |
Bright Cellars, AmFam, Coinigy & More: This Week’s WI Watchlist | Jeff Buchanan | 05/18/18 | Wisconsin |
FluGen to Study Versatility of Its Universal Flu Vaccine Candidate | Jeff Buchanan | 05/17/18 | Wisconsin |
FluGen May Seek Funding from $12M Gates-Backed Flu Vaccine Challenge | Jeff Buchanan | 05/01/18 | Wisconsin |
Exact Sciences: Severe Flu Season Slows Down Cancer Test’s Sales | Jeff Buchanan | 02/26/18 | Wisconsin |
15 For ’18: Key Clinical Data to Watch For Next Year (Part 2) | Alex Lash | 12/06/17 | National |
Fresh Off New Funding Round, FluGen Plans 3 Clinical Trials for 2018 | Jeff Buchanan | 08/04/17 | Wisconsin |
Visterra, Braeburn Stumble After Solid ’17 Start for Bio IPOs | Ben Fidler | 02/10/17 | Boston |
Flu Research, Propeller, & Stem Cells: This Week’s WI Watchlist | Jeff Buchanan | 05/31/16 | Wisconsin |
After Reinvention, Pulmatrix Wraps Up Ruthigen Deal, Heads to Nasdaq | Ben Fidler | 06/16/15 | Boston |
Officials Say Fuji’s Purchase of Kalon Boosts Texas’s Biotech Profile | Angela Shah | 12/22/14 | Texas |
East Coast Biotech Roundup: Intarcia, Atlas, Visterra, & More | Ben Fidler | 10/06/14 | Boston |
WI-based FluGen Raises $3.4M For Universal Flu Vaccine Phase I Trial | Jeff Bauter Engel | 06/02/14 | Wisconsin |
Myriad RBM Test Helping to Mine Secrets of Normal Immune System | Bernadette Tansey | 04/16/14 | Texas |
Lucigen Takes On Diagnostic Giants With On-the-Spot Pathogen Tests | Jeff Bauter Engel | 01/30/14 | Wisconsin |
Theraclone Merges With PharmAthene, Plans to Stay in Seattle | Luke Timmerman | 08/01/13 | Seattle |
East Coast Life Sciences Roundup: GSK, Protein Sciences, IMS Health | Bernadette Tansey | 03/15/13 | Boston |
IDRI, Medicago To Test Self-Injectable Pandemic Flu Vaccine | Luke Timmerman | 08/16/12 | Seattle |
Theraclone Takes 2nd Antibody into the Clinic Against Common Virus | Luke Timmerman | 06/14/12 | Seattle |
Theraclone Passes First Clinical Test with Flu-Fighting Antibody | Luke Timmerman | 05/15/12 | Seattle |
Theraclone Names Cliff Stocks, Vet of Icos & Calistoga, as New CEO | Luke Timmerman | 12/06/11 | Seattle |
UW Scores $40M for Biofuels, Cocrystal’s Fight Against HepC, The Women’s Biotech Network, & More Seattle-Area Life Sciences News | Luke Timmerman | 09/29/11 | Seattle |
The Immunex Impact, Calypso Gets Acquired, Women in Bio’s Kickoff, & More in Seattle-Area Life Sciences News | Luke Timmerman | 09/22/11 | Seattle |
Theraclone Enters Clinical World, With Flu Antibody That Might Be Handy in Pandemic | Luke Timmerman | 09/21/11 | Seattle |
NYC’s Vivaldi, Allied With Harvard and San Francisco VC Firm, Forge a New Way to Fight the Flu | Arlene Weintraub | 04/28/11 | New York |
VBI Progressing with Vaccines That Don’t Require Refrigeration | Ryan McBride | 03/24/11 | Boston |
Gates Foundation Makes First Equity Investment in a Biotech Startup, Liquidia Technologies | Luke Timmerman | 03/08/11 | Seattle |
Theraclone Strikes $632M Deal With Pfizer to Discover Antibodies for Cancer, Infections | Luke Timmerman | 01/18/11 | Seattle |